All News
Liver damage is NOT an extra-articular manifestation of RA BUT the ff'g factors are associated with liver disease in RA & can complicate management👇@RheumNow #ACR20 https://t.co/RqL69iVJpC
sheila RHEUMarampa ( View Tweet)
What is refractory RA? Inability to reach #T2T goals of remission or at least LDA despite various changes of tx. "We should aim at best care for the tx of refractory RA"-Prof.Josef Smolen @RheumNow #ACR20 https://t.co/7Wxjd5t3Oi
sheila RHEUMarampa ( View Tweet)
Interesting study suggesting decreasing RF titers can be a biomarker to predict radiographic remission.
Will you change your practice to do serial RF measurements? @rheumnow #ACR20 #ACRbest https://t.co/MvxBv0Kdek
k dao KDAO2011 ( View Tweet)
Nintedanib for RA-ILD? In the INBUILD Trial, pts on Nintedanib did better than PBO, efficacy similar among autoimmune ILDs including RA. @RheumNow #ACR20 @joanbathon https://t.co/I4AJlemIhD
sheila RHEUMarampa ( View Tweet)
OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX)
Abstr#808 #ACR20 @rheumnow
https://t.co/TDmV0EJTp8
k dao KDAO2011 ( View Tweet)
SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I
sheila RHEUMarampa ( View Tweet)
ACPA+ RA should likely NOT taper bDMARDs as less Bio survival if ACPA+ &/or monoRx. Should EULAR guidelines be changed? What about retention with JAKis? #ACR20 @RheumNow @CRASCRRheum abstr804 https://t.co/vjzIIgVJ0s
Janet Pope Janetbirdope ( View Tweet)
In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX
sheila RHEUMarampa ( View Tweet)
Anti-PAD Abs seen in 1/3 of pts at-risk for RA and 1/3 of pts w/ CSA.
Implications? Possible predictive value of anti-PAD Abs in RA dse progression?
@RheumNow #ACR20 abs0761 #ACRbest https://t.co/VpkjwU2YZm
sheila RHEUMarampa ( View Tweet)
Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs
Janet Pope Janetbirdope ( View Tweet)
Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe. Abstr#0798 #ACR2020 compares Abrilada & Humira in RA @RheumNow @CRASCRRheum https://t.co/AUcVZnc6Gj
Janet Pope Janetbirdope ( View Tweet)
What is your initial csDMARD of choice in pts w/ elderly-onset RA? @RheumNow #ACR20
sheila RHEUMarampa ( View Tweet)
Serial RF titers? Abst#0754 from Japan: Pts with RF>45, tracked RF at month 0/4/12 after starting b/tsDMARD. 46/130 had RF decrease titers, had better radiographic remission/DAS28-ESR. Limits: varied Rx, More aggressive Rx w RF decrease grp @RheumNow. #ACR20
Eric Dein ejdein1 ( View Tweet)
#ACR20 @RheumNow. We think of dichotomy of erosive vs. non-erosive but Abst#0748 shows joint space narrowing precedes erosive disease and requires more attention for early recognition. https://t.co/JLd3xVTlXM
Eric Dein ejdein1 ( View Tweet)
Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
Eric Dein ejdein1 ( View Tweet)
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20
https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
Links:
Dr. John Cush RheumNow ( View Tweet)
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
sheila RHEUMarampa ( View Tweet)
Abst#0194 at #ACR20 showed that significant symptoms of depression in RA are more frequent than depression diagnosed clinically, suggesting that depression may go undiagnosed and that symptoms of depression predicted mortality in RA patients! @RheumNow https://t.co/GqwXNB45y2
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
ACPA+ and subclinical synovitis does not automatically mean developing to RA.
Interesting work by Cleo Rogier et al. Something to consider in pts w/arthralgias & when to start csDMARDs @RheumNow #ACR20 Abstr#481 #ACRbest https://t.co/q3vIITmtq2
sheila RHEUMarampa ( View Tweet)
